CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12345678910111213...39313932»
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Journal, Combination therapy:  A Case of Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab. (Pubmed Central) -  Oct 2, 2024   
    The treatment was temporarily discontinued owing to immune-related adverse events, such as rash, and the patient was subsequently managed with systemic steroid therapy; however, the disease progressed after two courses of this treatment. Further studies are needed to validate the efficacy and safety of immune checkpoint inhibitors such as durvalumab and tremelimumab for the treatment of unresectable combined hepatocellular cholangiocarcinoma.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Monjuvi (tafasitamab-cxix) / Incyte, Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
    Journal:  How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. (Pubmed Central) -  Oct 2, 2024   
    If relapse occurs despite this or alternative therapies are preferred, many novel therapeutic options and combinations exist with some potential modifications for older adults, such as bispecific antibodies, tafasitamab and lenalidomide, polatuzumab containing regimens, or loncastuximab tesirine. This article provides a summary of our approach to the management of this diverse population of older patients with relapsed or refractory DLBCL.
  • ||||||||||  Cablivi (caplacizumab) / Sanofi, Rituxan (rituximab) / Roche
    Review, Journal:  Refining the standard of care in immune thrombotic thrombocytopenic purpura. (Pubmed Central) -  Oct 2, 2024   
    iTTP survivors receiving PE and immunosuppression alone are at a heightened risk for stroke, other cardiovascular disorders, neurocognitive impairment, and kidney disease. Whether rapid prevention of VWF multimer/platelet formation with caplacizumab can suppress such long-term sequelae, and whether caplacizumab can replace PE in initial therapy, are under investigation.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Lynparza (olaparib) / Merck (MSD), AstraZeneca, Aliqopa (copanlisib) / Bayer
    Journal:  Characterization of Anticancer Drug Protomers Using Electrospray Ionization and Ion Mobility Spectrometry-Mass Spectrometry. (Pubmed Central) -  Oct 2, 2024   
    Ion mobility-mass spectrometry and density functional theory revealed that these compounds generate isomers during ionization (protomers) due to the presence of multiple protonation sites within their chemical structures. Our work has implications for understanding the solution- and gas-phase chemistry of these molecules during spray-based ionization processes.
  • ||||||||||  Kimmtrak (tebentafusp-tebn) / Immunocore
    Review, Journal, IO biomarker:  Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches (Pubmed Central) -  Oct 2, 2024   
    New drugs undergoing clinical trials are mostly targeted drugs designed to inhibit the protein products of mutant genes or immunotherapeutic agents designed to stimulate the immune response against specific antigens. In addition to these approaches, potential therapeutic targets of epigenetic regulation of UM development are considered in the review.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Preclinical, Journal:  Synergistic effect of bazedoxifene and abemaciclib co?treatment in triple?negative breast cancer cells in vitro. (Pubmed Central) -  Oct 2, 2024   
    Both abemaciclib and bazedoxifene monotherapies inhibited cell cycle progression and cell viability, migration and invasion, and induced apoptosis; however, the combination treatment exerted a greater effect than either monotherapy. These findings support the concept of CDK4/6 and IL-6 dual inhibition as a novel targeted therapy against TNBC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Monotherapy, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Long-term treatment results of pembrolizumab monotherapy: reconsideration of immune checkpoint inhibitor monotherapy. (Pubmed Central) -  Oct 2, 2024   
    On multivariate analysis, histology, PD-L1 TPS, and irAEs were significant prognostic factors. Pembrolizumab monotherapy demonstrated promising treatment outcomes for advanced or recurrent NSCLC, as evidenced by the significant association of PD-L1 TPS with irAEs and prognosis, suggesting its potential as a beneficial therapeutic option.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Elevated neopterin and decreased IL-4, BDNF levels and depression in lymphoma patients receiving R-CHOP chemotherapy. (Pubmed Central) -  Oct 2, 2024   
    In conclusion, the present study suggests a potential link between elevated neopterin levels, decreased IL-4, and BDNF levels, and the presence of depression in lymphoma patients receiving R-CHOP chemotherapy. This study provides valuable insights into understanding the emotional challenges faced by cancer patients, offering information for more personalized interventions and comprehensive support approaches within the oncology setting.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    PATTERNS OF FATIGUE IN ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK HODGKIN LYMPHOMA () -  Oct 2, 2024 - Abstract #SIOP2024SIOP_1533;    
    These findings likely reflect early reduction in disease burden and associated functional gains, followed by increased cumulative treatment burden. Future comparisons across treatment regimens (e.g., steroid-including versus steroid-sparing regimens) will facilitate assessment of associations between treatment exposure and fatigue.
  • ||||||||||  Rituxan (rituximab) / Roche
    RITUXIMAB WITH HIGH-DOSE METHOTREXATE FOR THE TREATMENT OF BURKITT LYMPHOMA IN MALAWI. () -  Oct 2, 2024 - Abstract #SIOP2024SIOP_1010;    
    Rituximab was associated with longer time-to-neutrophil recovery, without increased serious bacterial infections. Although more treatment-related deaths were observed with rituximab, it was not statistically significant, and additional follow-up data is needed.
  • ||||||||||  Tzield (teplizumab-mzwv) / Sanofi
    Teplizumab in children with newly diagnosed type 1 diabetes (T1D): outcomes from the Phase 3 PROTECT study (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1192;    
    P3
    70 deaths were reported from 238 patients; 27 (33%) on NR, (28 (33%) on LD and 15 (21%) on SD.Conclusions Whilst there was no difference in CCR or survival between trial arms overall, the addition of SD to chemotherapy significantly improved CCR and survival in malnourished children with eBL. The PROTECT study showed that teplizumab reduced the decline in ?-cell function and resulted in measurable clinical benefits that were sustained through 78 wks.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Revisiting an ovine model for in utero repair of gastroschisis (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_742;    
    We report six surviving lambs, with four lambs undergoing in utero repair and two repaired at EXIT. Preliminary barium motility and necropsy data suggests in utero repair of gastroschisis may improve postnatal bowel motility and reduces intestinal adhesions.
  • ||||||||||  Rituxan (rituximab) / Roche
    The "Missing Link" In A Case Of Mastoiditis (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_680;    
    At 5 months post-discharge, our patient has completed 4 doses of Rituximab and continues to require daily prednisolone and azathioprine. Although rare in children, providers should consider GPA in pediatric patients with persistent symptoms involving the upper and lower respiratory tracts or kidneys, as early treatment leads to improved outcomes.
  • ||||||||||  Rituxan (rituximab) / Roche
    Small Vessels, Big Impact: A Patient with Granulomatosis with Polyangiitis (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_678;    
    Severe refractory asthma exacerbations, numerous ENT symptoms, renal disease, and detection of specific antibodies served as key indicators for diagnosing GPA. Timely initiation of treatment with immunosuppressive medications and utilization of ECMO proved to be lifesaving interventions.
  • ||||||||||  Rituxan (rituximab) / Roche
    Non-Hodgkin Lymphoma Presenting as Abdominal Pain in an Adolescent Female (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_665;    
    To our knowledge, this is a rare report of a pediatric case of B cell NHL presenting with primary abdominal tumor with ovarian involvement. Prognosis for NHL is approximately 90% 5-year survival for individuals under the age of 20, with little recurrence (4).
  • ||||||||||  Nplate (romiplostim) / Amgen
    A Rare Cause of Short-Rib Thoracic Dysplasia in a Neonate (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_636;    
    While many conditions in the differential are mainly skeletal disorders, SDS has multisystem involvement that can be life-threatening if not caught early. A high index of suspicion is necessary to recognize this condition in the neonatal population.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC. (Pubmed Central) -  Oct 2, 2024   
    Treatment of nivolumab alleviated the protective effects of MGAT5 on CTL activity...Consequently, we propose that MGAT5 could serve as a biomarker to predict patients' responses to anti-PD-1 therapy. Furthermore, targeting the branched N-glycans at N35 and N200 of PD-L1 may lead to the development of novel diagnostic and therapeutic approaches.